Loading stock data…
Spero Therapeutics (SPRO)
$1.19+0.03 (+2.59%)
After Hours$1.19+0.00 (+0.00%)· Last close Jul 24
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Spero Therapeutics, Inc. in the Healthcare sector is trading at $1.19 with a market capitalization of $162M. Wall Street consensus targets $4.00 (1 analysts), implying a +236.1% move over the next 12 months. The stock is currently near its 52-week low of $1.08, remaining 50.2% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality. Risk note: RSI 10 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +236.1% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 10) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $258,000↓ | $39.66M↑ | $3.05M↓ | $11.80M↑ | $5.11M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$7.54M↓ | $31.41M↑ | -$7.33M↓ | -$2.36M↑ | -$14.56M |
| Net Income | -$7.20M↓ | $31.52M↑ | -$7.38M↓ | -$1.70M↑ | -$13.87M |
Peer Comparison
JNJUNHPFE
Fundamentals
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$162.41M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
28.78%
Volume
Today's trading volume
11.74M
Recent News
Innovent licenses IBI355 rights to Spero for up to $1.1bn
Spero will hold rights to the antibody in all markets except Mainland China, Hong Kong, Macau, and Taiwan.
J&J dips despite upbeat outlook; AstraZeneca, Spero cut China deals
J&J’s shares ticked down as oncology sales missed expectations. Elsewhere, AstraZeneca bet $600 million on a lung cancer drug and a pair of biotechs snagged two of the year’s top venture rounds.
Spero Therapeutics Lands $105 Million Royalty Financing to Advance SP001 Development (SPRO)
Spero Therapeutics, Inc. (NASDAQ:SPRO) has entered into a $105 million non-recourse, non-dilutive royalty financing agreement with affiliates of HealthCare Royalty (HCRx), a company majority owned by KKR & Co.
GSK (LSE:GSK) Wins FDA Approval For Utebzi As Momelotinib Gains Orphan Tag
GSK (LSE:GSK) and Spero Therapeutics received U.S. FDA approval for Utebzi, a first in class oral carbapenem antibiotic for complicated urinary tract infections. Utebzi offers an oral treatment option where patients have often relied on intravenous antibiotics for multi drug resistant infections. The U.S. FDA also granted Orphan Drug Designation to GSK's momelotinib for treating VEXAS syndrome, a rare blood disorder. For investors tracking GSK, these two regulatory milestones highlight the...
Is GSK plc (GSK) Expanding Its Anti-Infectives Leadership With New FDA-Approved Therapy?
We recently compiled a list of the 10 Best Weight Loss Drug Stocks to Buy in 2026. GSK plc (NYSE:GSK) is one of the best weight loss drugs on this list. TheFly reported on June 17 that GSK and Spero Therapeutics announced that the U.S. Food and Drug Administration approved Utebzi for the treatment of complicated urinary tract infections, including […]